To study the frequency distribution of cytochrome P450 (CYP) functional genetic variants in five Eurasian populations from the territory of Siberia in Russia. Materials & Methods: Unrelated healthy Tuvinians, Buryats, Altaians, Yakuts and Russians (n = 87-88) were genotyped for CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C19*3, CYP3A5*3 and CYP3A5*6. Standard pairwise genetic distances, locus-specific and global Fst statistics were calculated. Results: CYP allele and genotype frequencies demonstrated significant variability. Overall, the degree of between-population variance displayed by CYP SNPs was lower than that recorded from neutral short tandem repeats and Aluinsertion polymorphism, indicating evolutionary conservation of CYP polymorphisms. CYP-based genetic distances were well correlated with the geographic distances across populations (r = 0.822, p = 0.008). Conclusions: Although the tested variants were present in the neighboring, yet secluded, populations at the expected range of frequencies, the observed frequencies were significantly variable across Eurasian populations, indicating potential relevance to clinical decision making.
The appropriate class, dose and treatment regimen that lead to optimal therapeutic safety and efficacy are presumed to be governed, at least partially, by genetic determinants. Thus, it is expected that, in the future, genetic markers will serve as diagnostics, informing and guiding clinical decision making. Based on this principle, pharmacogenetic research is aimed at identifying individuals who are expected to benefit from a certain pharmacotherapy, while dramatically reducing the suffering and costs associated with adverse drug reactions (ADRs). Indeed, it has been stated that most of the commonly used drugs are effective in only 25-60% of patients, and more than 2 million cases of ADRs occur annually in the USA, including 100,000 deaths [1] .
From the early years up to contemporary pharmacogenetic research, genes encoding proteins that take part in the pharmacokinetics of drugs have been the focus of research. Among these genes the most prominently studied molecule group has indisputably been the drugmetabolizing enzymes (DMEs), predominantly the cytochrome P450 (CYP) family, since it is responsible for the oxidative metabolism of most drugs administered into the human body. A large body of evidence collected over the previous decades by various independent groups shows a direct impact of functional variations in DMEs on the pharmacokinetics of drugs metabolized by these enzymes [2, 3] . The above observations have led many to argue that patients' genotypes with regard to the key DME genes should be incorporated into clinical decision making [4, 5] . In fact, several drug labels already include recommendations for genotyping prior to treatment initiation and during follow-up (for example, the anticoagulant warfarin [6] ).
Despite the growing progress in pharmacogenetic research and pioneering examples of its impact on daily clinical management, many countries worldwide still lack the appropriate resources for individual genotyping and incorporation of routine pharmacogenetic testing into their national healthcare systems. It has thus been suggested that American-and European-based genetic knowledge would be applicable to the health management of the developing world, until resources are identified for the development of nation-specific pharmacogenetic profiles in these countries [7] . Indeed, many countries rely on the US FDA/European Medicines Agency (EMEA) for safety and dosing guidance, disregarding specific consideration related to non-American and non-European populations. This is a crucial point, as reported allele and genotype frequencies for one population are not necessarily applicable to other, even similarly defined, populations (for example, allele frequencies of the glutathione-S-transferase isoenzyme θ gene [GSTT1] range from 13-28% amongst Caucasian populations [8] ). It is thus essential to Pharmacogenomics (2008) 9(7) future science group future science group evaluate and demonstrate the utility of global genetic profiles in geographically and ethnically distinct populations.
Siberia possesses unique demographic characteristics of massive ethnic heterogeneity, resulting from a legacy of centuries of interface and communication between Caucasoids and Mongoloids. The disproportionate distribution of small populations across an extensive stretch of territory (average population density of approximately three individuals per square kilometer) lead some autochthonous groups to remain anthropologically, linguistically and genetically different from each other. Most of the modern population in Siberia is composed of Russians (Slavs), while the remaining indigenous populations, including Buryats, Tuvinians, Yakuts and Southern Altaians, belong to Mongoloid and Turkic-speaking groups, who have retained their native language and ethnic identity throughout history, resulting in minimal interethnic admixture. To this end, it is customary in the scientific literature to relate to Eurasian populations as roughly a unified entity, without distinction between subpopulations that might be subject to unique genetic pressures resulting in differential genetic profiles and, thus, potentially requiring uniquely tailored pharmacotherapies. We therefore set out to investigate whether known clinically relevant variations in DMEs from the CYP family exhibit unique genetic properties in five distinct Eurasian populations.
Materials & methods

Study population
A total of 438 blood samples from apparently healthy, unrelated individuals were collected from the following five autochthonous groups from the territory of Siberia in Russia: Southern Altaians (n = 87) residing in the village of Beshpeltir of the Altai republic; Tuvinians (n = 88) residing in Kyzil; Buryats (n = 88) from the Okinski and Kizhinginsky districts of the Buryatia Republic; Yakuts (n = 88) from the village of Cheriktei in the Sakha (Yakutia) Republic; and Russians (n = 87) residing in Tomsk (a city in which approximately 90% of the population is Russian). A map of Russia indicating the geographical residence of each of the study's populations is presented in Figure S1 in the Supplementary Material. DNA samples were obtained from the DNA bank of the Research Institute of Medical Genetics in Tomsk, Russia. Blood samples were collected from volunteers throughout the last 15 years. Equal proportions of men and women in each population were selected for the current study. In order to ensure the lack of cryptic relatedness amongst individuals, only samples from unrelated individuals as depicted in genealogical analysis of at least the last three generations were selected for genotyping. The study was approved by the Institutional Review Board of the Research Institute of Medical Genetics (Tomsk, Russia). Written informed consent was obtained from the volunteers before blood sampling.
Genotyping
Total genomic DNA was extracted from whole blood using the perchlorate/chloroform method [9] . DNA quantity and quality were assessed spectrophotometrically. All SNP variants were genotyped by TaqMan ® fluorescencebased allelic discrimination [10] . Premade assays offered as Assay-by-Demand were used when available; otherwise primers were designed using the Applied Biosystems (ABI; CA, USA) Assayby-Design tool. PCRs were carried out using the standard ABI protocol for a 5 µl reaction volume. Fluorescence spectra were detected by use of the 7900HT Fast Real Time PCR System, and the data was analyzed using the SDS software, version 2.2.2 (ABI). All genotype calls were determined independently by two researchers (Makeeva O and Grossman I), and ambiguous calls were regenotyped or discarded. Genotyping failure rates were approximately 1%. Alu and short tandem repeat (STR) genotyping assays and results have been published elsewhere [11] [12] [13] [14] [15] (available in English upon request). Characteristics of all polymorphic sites reported in this paper are provided in Table S1 -S4 of the Supplementary Material.
Statistical analysis
Allele and genotype frequencies were calculated by direct counting, and Hardy-Weinberg equilibrium was evaluated by an exact test [16] , as implemented in Arlequin version 3.1. [17] . Genetic variants for which deviations from Hardy-Weinberg equilibrium were identified were excluded from further analysis. Pairwise allele frequency comparisons were tested by Fisher's exact test and the Bonferroni correction was used for multiple tests. Pairwise and locusspecific Fst values and corresponding p-values were computed using Arlequin version 3.1. [18] [19] [20] . The Mantel test (10,000 permutations) [21] Table 2 .
As expected, Russians show a high similarity in allele frequencies of all the five polymorphic CYP variants to other European populations, exhibiting intermediate frequencies compared (Figure 1-3) . The CYP2C19*3 variant was absent in Russians, as well as in most other European populations (Figure 4 ). Our findings closely resemble the two previous publications reporting frequency information on the CYP2C9 and CYP2C19 polymorphisms in Russians [22, 23] . An overall high frequency of the CYP3A5*3 variant was detected (92%), which is typical in other Europeans (87-94%) ( Figure 5 ).
Highly significant differences in allele frequencies for CYP2C9*2 were detected between Russians and all native Siberian populations, except for Altaians (Tables 1 & 2) : 12% in Russians versus 1% in Tuvinians and Yakuts (p = 0.00002) and 2% in Buryats (p = 0.0003). The frequency of CYP2C9*3 was highest in Altaians, who had an allelic frequency of 9% of the variant allele, versus 1.7% in Buryats (p = 0.002) and 0.6% in Yakuts (p = 0.0001) (Tables 1 & 2) . The CYP2C19*2 and *3 variants are known to be more common in Asian than in European populations, where the *3 polymorphism is rare or absent (Figure 4 , [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] ). We report here that the CYP2C19*3 variant To further analyze the CYP polymorphism frequency distribution in our five Eurasian populations we compared the genetic versus geographic distances between each pair of populations. Two matrices of pairwise genetic (Nei's standard genetic distance) and geographic distances (in km) were obtained, and their correlation was evaluated using Mantel test statistics ( Figure 6 ). The analyses revealed that the CYPbased genetic distances exhibit a high and significant correlation with geographic distances between populations with a Mantel correlation coefficient, r = 0.822, p = 0.008.
Genetic relationships of Siberian populations amongst themselves & across other Caucasoid & Asian populations: principal component analysis
We assessed a genetic relationship among the populations under study, as well as their relatedness to other world populations (both Caucasoid and Asian) through principal component analysis (PCA; Figure 7) . Analysis of principal components showed a very compact cluster of several European populations, with Russians positioned in the middle. Native Siberian populations showed proximity to Europeans (especially Altaians and Tuvinians) when compared with other Asian populations analyzed (Koreans, Chinese and Japanese). Two principal components accounted for 99.7% of the genetic variance observed in CYP SNPs frequency. Tables S5-S9 in the Supplementary Material lists the source population sizes, reported allele frequencies and references. When several independent papers reported on the same population, the data was pooled together and calculated based on the total counts. World populations [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Studied in this paper
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Fst statistics: CYP SNPs versus Alu repeats & STR polymorphisms
To examine whether the functional CYP450 variant frequency spectrum was shaped by selection forces distinct from the evolution of neutral genetic regions, we calculated pairwise, locus-specific and global (over all studied SNPs) Fst statistics based on the above tested functional CYP450 variants, six neutral STR and seven randomly selected Alu polymorphisms in a subset of the samples. Distances of each Alu and STR marker from known genes are presented in Tables S3 & S4 of the Supplementary Materials (their frequency data was published previously [11] [12] [13] [14] [15] , and is available in English upon request). Alu and STR polymorphisms are widely used in population genetics and evolutionary studies, especially when both nonfunctional systems are analyzed simultaneously: Alu repeats exhibit a low mutation rate (stable evolution) and always display an ancestral state of an absence of insertion. STRs, on the other hand, are characterized by a high mutation rate and multiple alleles, useful in differentiation between closely related populations. World populations [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Studied in this paper [38] , and thus deserve a special focus before ascertainment of clinical applicability through programs such as the PharmacoGenetics for Every Nation Initiative (PGENI) [7] . This was launched with the purpose of constructing a complete database on gene variants that affect the efficacy or toxicity of drugs, together with information on frequencies of these variants in world populations (especially outside the USA and Europe). This database is expected to be useful to international organizations, such as the WHO, in targeting treatment recommendations to specific populations [7] .
Comprehensive comparison of frequencies between the current investigated samples and other populations throughout the world World populations [24] [25] [26] 33, [39] [40] [41] [42] [43] [44] [45] Studied in this paper
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future science group future science group indicates that, as expected, Russians were very close to other Europeans in allele frequencies of all the studied CYP450 polymorphisms. At the same time, some highly significant differences between Russians and indigenous Siberian populations were observed in allele frequencies of CYP2C9*2, CYP2C9*3, CYP3A5*3, CYP2C19*2 and CYP2C19*3 (Tables 1 & 2 (Figure 7) . The Mantel test revealed that CYP-based genetic distances exhibit a significant correlation with geographic distances.
It was previously shown that some of the genes of DMEs are likely targets of selective pressure, and thus show unusual patterns of variation frequency across human populations. This was specifically demonstrated for the CYP3A5 locus [39] . The CYP3A5*3 variant affects the conversion of cortisol to 6β-hydroxicortisol in the kidney, leading to higher reabsorption of sodium and water retention (and thus connected with the clinical phenotype of salt-sensitive hypertension). This functional effect confers a selective advantage when populations experience water shortages [40] .
Fixation indicies (F) statistics are used to assess differentiation among populations, as depicted by signatures in patterns of genetic variation [41] [42] [43] . Estimation of neutral Fst values was carried out based on a set of seven unlinked Alu repeats and six neutral STR loci (Table 3) . When the mode of selection is local adaptation, populations with similar selective regimes will acquire similar allele frequencies (yielding low Fst), whereas in others selection will drive allele frequencies apart (yielding high Fst). Global Fst Multiple independent reports indicating the potential clinical utility of CYP functional variant screening for the purpose of blood-level monitoring and patient response prediction have been published in recent decades. In this report we focused on CYP2C9, CYP2C19 and CYP3A5, for which common deficient alleles have been described, that have prominent potential to convey significant clinical utility. CYP2C9 hydroxylates approximately 16% of drugs in current clinical use [44] . Of special interest are those with a narrow therapeutic index, such as S-warfarin, tolbutamide and phenytoin, where impairment in CYP2C9 metabolic activity may require dose adjustment, as well as lead to severe toxicity. CYP3A5 has been indicated to have clinical relevance related to a range of therapeutics, including imatinib (an anticancer drug) and tacrolimus [45] (an immunodepressant). CYP2C19 poor metabolizers, comprising 3-4% of Caucasians and African-Americans, and 14-21% of Asians, may require dose adjustment for some tricyclic antidepressants, moclobemide, citalopram, diazepam and omeprazole [46] . The clinical outcome of duodenal ulcer treated with proton pump inhibitor-based, antiHelicobacter pylori regimens have been reported to vary according to CYP2C19 genotype as well [47] . The FDA has recently approved, for the first time, a genetic test, the AmpliChip CYP450 Test, prompting the CYP2C19 (and CYP2D6) gene variants to be prime candidates for diagnostic pharmacogenetic testing in clinical practice [46] . However, it should be mentioned, that there is currently not enough evidence to prove the utility of these tests in the clinical practice of several classes of antipsychotics and antidepressants [48, 49] .
Future perspective
The promise and utility of pharmacogenetic research to daily clinical care has been recognized by regulatory agencies both in the USA and in Europe. These developments are currently being integrated into recommendations and warnings included in the package inserts of marketed therapeutic formularies, as well as report recommendations and requirements for newly developed drugs in research and development phases [50, 51] . However, these proceedings apply to American and European countries only, creating the need for assessment of the impact and utility of these new tests in the rest of the world, where independent genotyping is currently impractical and financially prohibitive.
It should be stressed out that the proven utility of genotyping results need to be tested in clinical settings [51] , and in the final decision-making process, cost-effectiveness must also be considered. Under the assumption that such global 
Executive summary
Pharmacogenetics may serve as a globally applicable diagnostic tool
• It has been extensively demonstrated that there is a high frequency variability in functional CYP gene variants across various populations and ethnic groups.
• It is important to collect information on these clinically relevant pharmacogenetics variants in different areas of the globe.
• This genetic profile can assist healthcare organizations in the prioritization and selection of essential medicines on a national level, before individual pharmacogenetic testing will become feasible.
• Implementation of global pharmacogenetic plans, such as the PharmacoGenetics for Every Nation Initiative (PGENI; http://pgeni.unc.edu/), at this time can promote drug treatment safety and efficacy throughout the world.
Frequency distribution of clinically relevant CYP polymorphisms in different populations
• While studying CYP polymorphism frequency distribution in five Eurasian populations, it has been shown that CYP-based genetic distances are well correlated with their geographic distances.
• However, between-population variability was lower when compared with neutral genetic variants, and thus some fixation of the CYP alleles may be assumed, which can be due to selective pressure acting on these specific genome regions.
• Interpretation of drug-metabolizing enzymes genotyping results in one population cannot rely solely on screening of another representative population, but rather necessitates further exploration in subpopulations, specifically where variants are monomorphic in one population but not in others (as in the case of CYP2C19*3).
pharmacogenetic profiles may be ultimately assembled, which capture the majority of clinically relevant genetic variation applicable to the entire world population, initiatives such as PGENI [7] have been launched. Our findings indicate that, although allele frequencies may differ substantially across Eurasian subpopulations, adopting American/European-based pharmacogenetic profiles may indeed be of adequate utility as surrogates to individual genotype screening in the present day. We therefore believe that implementation of global pharmacogenetics plans at this time can promote drug treatment safety and efficacy throughput the world, laying the foundations for routine incorporation of pharmacogenetics testing into daily clinical management concerning all regions of the globe. 
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• Figure S1 • Tables S1-10 Figure S1 . Map of Russia denoting the location of residence for the studied populations.
1: Tuvinians; 2: Buryats; 3: Southern Altaians; 4: Yakuts; 5: Russians. Table S5 . Source information for Figure 1 listing the displayed populations, the CYP allele frequencies, the number of subjects studied and references: CYP2C9*2.
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